Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension

Overview

About this study

The purpose of this study is to characterize the clinical and hemodynamic response of PAH therapy in patients with atypical PAH and risk factors for left heart disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years of age.
  • Precapillary pulmonary hypertension with mean PA pressure > 20 mmHg and planned initiation of pulmonary arterial hypertension therapy.
  • No active treatment for precapillary pulmonary hypertension.
  • Ambulatory (not wheelchair / scooter dependent).
  • Presence of any risk factor for left heart disease will qualify for inclusion (either atrial fibrillation, body mass index > 30 kg/m^2, arterial hypertension, diabetes, coronary artery disease or age > 60 years).

Exclusion Criteria:

  • Significant chronic obstructive pulmonary disease that is a primary contributor to symptoms in the opinion of the investigator.
  • Ischemia thought to contribute to dyspnea in the opinion of the investigator.
  • Obstructive hypertrophic cardiomyopathy.
  • Known infiltrative cardiomyopathy (amyloid).
  • Constrictive pericarditis or tamponade.
  • Active myocarditis.
  • Complex congenital heart disease.
  • More than mild aortic or mitral stenosis.
  • Intrinsic (prolapse, rheumatic) valve disease with more than moderate mitral, tricuspid or aortic regurgitation.
  • Acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, INR > 1.7 in the absence of anticoagulation treatment.
  • Terminal illness (other than HF) with expected survival of less than 1 year.
  • Enrollment or planned enrollment in another therapeutic clinical trial in next 3 months.
  • Inability to comply with planned study procedures.
  • Pregnancy or breastfeeding mothers.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogesh Reddy, M.B.B.S.

Closed for enrollment

Contact information:

Louise Durst R.N.

(507) 284-1838

durst.louise@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20508806

Mayo Clinic Footer